Anti-CD3E therapeutic antibody (Pre-made Otelixizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Otelixizumab, also known as TRX4, is a monoclonal antibody,[1] which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx, Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-414-1mg	1mg	3090
GMP-Bios-ab-414-10mg	10mg	21890
GMP-Bios-ab-414-100mg	100mg	148000
GMP-Bios-ab-414-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-CD3E therapeutic antibody (Pre-made Otelixizumab biosimilar,Whole mAb)
INN Name	Otelixizumab
Target	CD3E
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2007
Year Recommended	2008
Companies	BTG;GlaxoSmithKline;Tolerx
Conditions Approved	na
Conditions Active	Type 1 diabetes mellitus
Conditions Discontinued	Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis
Development Tech	na